Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 134

1.

Helicase-primase inhibitor pritelivir for HSV-2 infection.

Wald A, Corey L, Timmler B, Magaret A, Warren T, Tyring S, Johnston C, Kriesel J, Fife K, Galitz L, Stoelben S, Huang ML, Selke S, Stobernack HP, Ruebsamen-Schaeff H, Birkmann A.

N Engl J Med. 2014 Jan 16;370(3):201-10. doi: 10.1056/NEJMoa1301150.

2.

Effect of Pritelivir Compared With Valacyclovir on Genital HSV-2 Shedding in Patients With Frequent Recurrences: A Randomized Clinical Trial.

Wald A, Timmler B, Magaret A, Warren T, Tyring S, Johnston C, Fife K, Selke S, Huang ML, Stobernack HP, Zimmermann H, Corey L, Birkmann A, Ruebsamen-Schaeff H.

JAMA. 2016 Dec 20;316(23):2495-2503. doi: 10.1001/jama.2016.18189. Erratum in: JAMA. 2017 Feb 14;317(6):648.

PMID:
27997653
3.

No Evidence of Pritelivir Resistance Among Herpes Simplex Virus Type 2 Isolates After 4 Weeks of Daily Therapy.

Edlefsen PT, Birkmann A, Huang ML, Magaret CA, Kee JJ, Diem K, Goldner T, Timmler B, Stoelben S, Ruebsamen-Schaeff H, Zimmermann H, Warren T, Wald A, Corey L.

J Infect Dis. 2016 Jul 15;214(2):258-64. doi: 10.1093/infdis/jiw129. Epub 2016 Apr 7.

4.
5.

Helicase-primase inhibitor pritelivir for HSV-2 infection.

Burrel S, Rouard C, Boutolleau D.

N Engl J Med. 2014 Apr 24;370(17):1663-4. doi: 10.1056/NEJMc1402071. No abstract available.

6.

Valacyclovir and acyclovir for suppression of shedding of herpes simplex virus in the genital tract.

Gupta R, Wald A, Krantz E, Selke S, Warren T, Vargas-Cortes M, Miller G, Corey L.

J Infect Dis. 2004 Oct 15;190(8):1374-81. Epub 2004 Sep 20.

PMID:
15378428
7.

Famciclovir reduces viral mucosal shedding in HSV-seropositive persons.

Leone P, Warren T, Hamed K, Fife K, Wald A.

Sex Transm Dis. 2007 Nov;34(11):900-7.

PMID:
17538513
8.

Pharmacokinetics-pharmacodynamics of the helicase-primase inhibitor pritelivir following treatment of wild-type or pritelivir-resistant virus infection in a murine herpes simplex virus 1 infection model.

Biswas S, Sukla S, Goldner T, Field HJ, Kropeit D, Paulsen D, Welbers A, Ruebsamen-Schaeff H, Zimmermann H, Birkmann A.

Antimicrob Agents Chemother. 2014 Jul;58(7):3843-52. doi: 10.1128/AAC.02641-14. Epub 2014 Apr 21.

9.

One-day regimen of valacyclovir for treatment of recurrent genital herpes simplex virus 2 infection.

Bavaro JB, Drolette L, Koelle DM, Almekinder J, Warren T, Tyring S, Wald A.

Sex Transm Dis. 2008 Apr;35(4):383-6. doi: 10.1097/OLQ.0b013e31815e4190.

PMID:
18362859
10.

Genital shedding of herpes simplex virus among symptomatic and asymptomatic persons with HSV-2 infection.

Tronstein E, Johnston C, Huang ML, Selke S, Magaret A, Warren T, Corey L, Wald A.

JAMA. 2011 Apr 13;305(14):1441-9. doi: 10.1001/jama.2011.420.

11.
12.

Oral herpes simplex virus type 2 reactivation in HIV-positive and -negative men.

Kim HN, Meier A, Huang ML, Kuntz S, Selke S, Celum C, Corey L, Wald A.

J Infect Dis. 2006 Aug 15;194(4):420-7. Epub 2006 Jul 12.

PMID:
16845624
13.

Standard-dose and high-dose daily antiviral therapy for short episodes of genital HSV-2 reactivation: three randomised, open-label, cross-over trials.

Johnston C, Saracino M, Kuntz S, Magaret A, Selke S, Huang ML, Schiffer JT, Koelle DM, Corey L, Wald A.

Lancet. 2012 Feb 18;379(9816):641-7. doi: 10.1016/S0140-6736(11)61750-9. Epub 2012 Jan 4. Erratum in: Lancet. 2012 Feb 18;379(9816):616.

14.

Effect of ASP2151, a herpesvirus helicase-primase inhibitor, in a guinea pig model of genital herpes.

Katsumata K, Chono K, Sudo K, Shimizu Y, Kontani T, Suzuki H.

Molecules. 2011 Aug 25;16(9):7210-23. doi: 10.3390/molecules16097210.

15.

Topical resiquimod 0.01% gel decreases herpes simplex virus type 2 genital shedding: a randomized, controlled trial.

Mark KE, Corey L, Meng TC, Magaret AS, Huang ML, Selke S, Slade HB, Tyring SK, Warren T, Sacks SL, Leone P, Bergland VA, Wald A.

J Infect Dis. 2007 May 1;195(9):1324-31. Epub 2007 Mar 16.

PMID:
17397003
16.

Once daily valacyclovir for reducing viral shedding in subjects newly diagnosed with genital herpes.

Martens MG, Fife KH, Leone PA, Dix LP, Brennan CA.

Infect Dis Obstet Gynecol. 2009;2009:105376. doi: 10.1155/2009/105376. Epub 2009 Aug 10.

17.

Suppression of subclinical shedding of herpes simplex virus type 2 with acyclovir.

Wald A, Zeh J, Barnum G, Davis LG, Corey L.

Ann Intern Med. 1996 Jan 1;124(1 Pt 1):8-15.

PMID:
7503497
18.

Once-daily valacyclovir to reduce the risk of transmission of genital herpes.

Corey L, Wald A, Patel R, Sacks SL, Tyring SK, Warren T, Douglas JM Jr, Paavonen J, Morrow RA, Beutner KR, Stratchounsky LS, Mertz G, Keene ON, Watson HA, Tait D, Vargas-Cortes M; Valacyclovir HSV Transmission Study Group.

N Engl J Med. 2004 Jan 1;350(1):11-20.

19.

Frequent genital herpes simplex virus 2 shedding in immunocompetent women. Effect of acyclovir treatment.

Wald A, Corey L, Cone R, Hobson A, Davis G, Zeh J.

J Clin Invest. 1997 Mar 1;99(5):1092-7.

20.

High-dose valacyclovir decreases plasma HIV-1 RNA more than standard-dose acyclovir in persons coinfected with HIV-1 and HSV-2: a randomized crossover trial.

Perti T, Saracino M, Baeten JM, Johnston C, Diem K, Ocbamichael N, Huang ML, Selke S, Magaret A, Corey L, Wald A.

J Acquir Immune Defic Syndr. 2013 Jun 1;63(2):201-8. doi: 10.1097/QAI.0b013e3182928eea.

Supplemental Content

Support Center